La cadena de opciones muestra datos clave de las opciones de acciones de Kairos Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Kairos Pharma..

Kairos Pharma (AMEX:KAPA) Bolsa, Cadena de Opciones

Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Kairos Pharma Ltd

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Equal-Weight rating and announces Price Target of $55.

News

Price Target

Initiation

Analyst Ratings

DOCS

Stephens & Co. Initiates Coverage On Doximity with Equal-Weight Rating, Announces Price Target of $55

Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) analysts are highlighting the company&#8217;s new turnaround plan under CEO Elliott Hill with a focus on inventory, product innovation and wholesale partnerships being key takeaways Friday following the company&#8217;s<a href="https://www.benzinga.com/general/sports/24/12/42605414/nike-q2-earnings-revenue-beat-eps-beat-shares-jump-nike-being-nike-again"> second-quarter financial report.</a>
The Nike Analysts: Telsey analyst Cristina Fernández downgraded Nike shares from Outperform to Market Perform and lowered the price target from $93 to $80.
JPMorgan analyst Matthew Boss maintained a Neutral rating and a price target of $73.
Goldman Sachs analyst Brooke Roach reiterated a Buy rating and lowered the price target from $97 to $91.
Needham analyst Tom Nikic reiterated a Buy rating and a price target of $84.
Truist analyst Joseph Civello reiterated a Buy rating and lowered the price target from $97 to $90.
Piper Sandler analyst Anna Andreeva maintained a Neutral rating and a price target of $72.
Bank of America analyst Lorraine Hutchinson reiterated a Buy rating and lowered the price target from $95 to $90.
Read Also: <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">Nike&#8217;s New CEO Blames Promotions For Declining Profits, Says Turnaround Efforts May Hurt As Company Moves To Clear Excess Inventory: &#8216;We Lost Our Obsession With Sport&#8217;</a>
Telsey on Nike: A turnaround path for Nike is in place, but may take longer than expected and could be costly, Fernández said in a new investor note.
The analyst said the turnaround path could require larger investments in brand marketing and hurt sales and profitability over the next year.
"In addition, we lack clarity around the length of time it will take to clean up inventory, introduce significant product newness, rebuild wholesale partnerships, and elevate Nike digital by reducing promotions in order to return Nike to growth," Fernández said.
Fernandez said there is "some early progress" with marketing and products, but things remain in the early stages.
JPMorgan on Nike: With guidance below analyst consensus, Nike could be setting up for a "crawl, walk, run setup," Boss said in a new investor note.
The phases are broken down as a crawl in fiscal year 2025 to complete the franchise lifecycle management, a walk phase in fiscal 2026 with new product innovation and run in fiscal 2027 with innovation and a look for the right partners.
"We see an elongated timeline for Nike to re-accelerate revenue growth in the midst of a franchise product lifecycle transition with the global macro backdrop further complicating the path forward," Boss said.
The analyst said the new CEO&#8217;s plan will include additional investment and wholesale discounts to get rid of excess inventory, which could result in higher promotional activity.
Goldman Sachs on Nike: The apparel company is taking immediate action under new CEO Hill, Roach said in a new investor note.
"We think the actions outlined today are the appropriate strategic moves to reset Nike to return to future growth," Roach said.
The analyst said Nike is beginning to show improvement in several areas, but inventory remains a key concern moving forward.
"We believe that the combination of a return to marketing growth, investing in the key city strategy and reestablishing partnership with wholesale partners are appropriate in the long term."
Needham on Nike: Second-quarter financial results were better than expected, Nikic said in a new investor note.
The analyst said Hill outlined the Nike vision that will be challenging in the near term.
"Climbing back up the ‘Hill' will be tough, but the path is clear," Nikic said.
Nikic added that Hill coming back to Nike is similar to a veteran athlete coming out of retirement to rescue a fallen sports team.
The analyst said Hill's commentary on re-establishing key wholesale partnerships could be encouraging for Foot Locker Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>), who is the company's largest wholesale partner.
Truist on Nike: Sentiment in Nike could be bottoming with the turnaround plan underway, Civello said in a new investor note.
The analyst said Hill's turnaround efforts put pressure on the second half 2025 outlook but could lead to more beat and raise guidance opportunities in the future and accelerate the timeline for a return to growth.
"We're encouraged about the team's sense of urgency and their strategic focus areas, especially improving wholesale positioning, elevating Nike's Direct business and refocusing marketing on bolder brand stories," Civello.
The analyst said Hill's decision to "rip off the Band-Aid" is great and could improve the turnaround plan.
Piper Sandler on Nike: The apparel company is in the early innings of a turnaround, Andreeva said in a new investor note.
"Doing the right things, but getting back to winning takes time," Andreeva said.
The analyst said Nike's third and fourth quarters will be hit hard for sales and profitability as the company makes room for new products and innovation.
"We view the move as necessary but also creating potentially longer-lasting lack of visibility."
Bank of America on Nike: Hill's strategy to reduce inventory to make way for new product innovation is the right Nike strategy, Hutchinson said in a new investor note.
"The anticipated reset sets the stage for a healthier Nike," Hutchinson said.
The analyst said this move will reduce profitability in the near-term while creating a "healthier business" in the long term.
NKE Price Action: Nike stock is down 0.44% to $76.75 on Friday versus a 52-week trading range of $70.75 to $123.30. Nike stock is down 29% year-to-date and has fallen 24% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42562515/nike-q2-earnings-preview-analyst-says-athletic-brand-early-in-turnaround-journey-with-new-ceo">Nike Q2 Earnings Preview: Analyst Says Athletic Brand Early In &#8216;Turnaround Journey&#8217; With New CEO</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Downgrades

Reiteration

Trading Ideas

Nike Stock Turnaround Path Clear, Analyst Says: 'Getting Back To Winning Takes Time'

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped <a href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges">obesity drug, CagriSema. </a>
To put the move in perspective, the only steeper plunge in the Danish pharma giant's history was a 26.2% collapse during the infamous Black Monday crash of October 1987.
Once the poster child of the obesity drug boom, Novo failed to meet the market's sky-high expectations, sparking a $20 billion wipe out in market value.
Here's what happened—and why some analysts believe Wall Street might have overreacted.
<h3 class="wp-block-heading">Trial Results Fall Short of High Expectations</h3>
CagriSema, a combination of cagrilintide and semaglutide, is part of Novo Nordisk's REDEFINE clinical program, designed to compete in the lucrative obesity drug market. 
The REDEFINE 1 Phase 3 trial, which involved 3,417 participants with obesity or overweight conditions, demonstrated a 22.7% weight loss after 68 weeks for patients taking CagriSema. 
While impressive compared to the 2.3% weight loss with placebo, the result was slightly below Novo's previously teased goal of a 25% reduction.
By comparison:
<ul>
<li>CagriSema: 22.7% weight loss</li>
<li>Semaglutide alone: 16.1% weight loss</li>
<li>Cagrilintide alone: 11.8% weight loss</li>
<li>Placebo: 2.3% weight loss</li>
</ul>
Additionally, 40.4% of patients taking CagriSema lost at least 25% of their body weight, compared to just 16.2% with semaglutide and a negligible 0.9% with placebo.
While the trial data were statistically significant, they fell shy of the hype surrounding Novo's claims that CagriSema could deliver 25% weight loss without added side effects.
<h3 class="wp-block-heading">Analysts Call The Selloff &#8216;Overdone&#8217;</h3>
Despite the sharp decline, several industry insiders believe the market overreacted. 
Maurits Pot, founder of Tema ETFs, which manages the GLP-1 Obesity &amp; Cardiometabolic ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTS#NYSE">HRTS</a>), told Benzinga: "This is the latest major event in the obesity space in what has proven to be a very volatile second half of the year.&#8221;
Tema ETFs had already been underweight Novo, holding just a 3.99% stake prior to the REDEFINE 1 results. 
Pot has been for long championing the case that the weight-loss market is far from being dominated by a duopoly – Novo Nordisk and Ely Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
&#8220;This latest readout from Novo today underscores why only betting on NOVO and LLY in the GLP-1 is very risky and has not worked in the second half of 2024,&#8221; he stated.
Despite this, he described Novo Nordisk&#8217;s sharp selloff as an &#8220;overreaction&#8221; and told Benzinga that the HRTS fund is taking advantage of Friday&#8217;s dip to add more shares.
Goldman Sachs analyst James Quigley offered a similar perspective in a note released Friday.
"While these weight loss data are lower than hoped in the market, we still believe that the product [CagriSema] will be filed and approved by the FDA,&#8221; Quigley stated.
The expert sees Novo's market position moving &#8220;from one where they had a clearly inferior product in Wegovy to one that is on par with Zepbound in terms of weight loss.&#8221;
&#8220;We see the share price move as overdone and with CagriSema offering another high efficacy option, it could still protect part of the longer term obesity franchise,&#8221; he added. 
Goldman maintained a bullish stance on Novo Nordisk, setting a 12-month price target of $148 for the ADR—a potential 75% upside from Friday's market price.
NVO Price Action: Shares of Novo Nordisk were down 18.5% to $84.25 at the time of publication Friday.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Photo: Shutterstock

Equities

Regulations

Sector ETFs

Eurozone

Health Care

Exclusives

Movers

ETFs

HRTS

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight rating.

VEEV

Stephens & Co. Initiates Coverage On Veeva Systems with Overweight Rating

Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) has outperformed the market over the past 10 years by 13.5% on an annualized basis producing an average annual return of 24.52%. Currently, Palo Alto Networks has a market capitalization of $124.88 billion. 
Buying $1000 In PANW: If an investor had bought $1000 of PANW stock 10 years ago, it would be worth $9,063.10 today based on a price of $190.31 for PANW at the time of writing.
<h3>Palo Alto Networks's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734713328_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PANW

Here's How Much You Would Have Made Owning Palo Alto Networks Stock In The Last 10 Years

Financial giants have made a conspicuous bullish move on NVIDIA. Our analysis of options history for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) revealed 608 unusual trades.
Delving into the details, we found 19% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 34 were puts, with a value of $1,595,963, and 574 were calls, valued at $192,107,595.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $0.5 and $280.0 for NVIDIA, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NVIDIA's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NVIDIA's whale activity within a strike price range from $0.5 to $280.0 in the last 30 days. 
<h3>NVIDIA Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734713248_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$17.25</td>
<td>$17.1</td>
<td>$17.25</td>
<td>$120.00</td>
<td>$776.2K</td>
<td>385</td>
<td>626</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$89.2</td>
<td>$88.95</td>
<td>$89.2</td>
<td>$44.00</td>
<td>$749.2K</td>
<td>1.7K</td>
<td>438</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$89.4</td>
<td>$88.85</td>
<td>$88.88</td>
<td>$48.00</td>
<td>$746.6K</td>
<td>7.2K</td>
<td>438</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$2.51</td>
<td>$2.5</td>
<td>$2.51</td>
<td>$135.00</td>
<td>$268.8K</td>
<td>40.0K</td>
<td>23.8K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.29</td>
<td>$138.00</td>
<td>$204.4K</td>
<td>13.2K</td>
<td>7.7K</td>
</tr>
</tbody>
</table>

<h3>About NVIDIA</h3>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
After a thorough review of the options trading surrounding NVIDIA, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is NVIDIA Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 106,796,164, the NVDA's price is up by 2.49%, now at $133.94. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>What The Experts Say On NVIDIA</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $190.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for NVIDIA, targeting a price of $190. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on NVIDIA, which currently sits at a price target of $175. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on NVIDIA, which currently sits at a price target of $220. 
&#x2A; An analyst from Wedbush persists with their Outperform rating on NVIDIA, maintaining a target price of $175. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on NVIDIA, which currently sits at a price target of $190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest NVIDIA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

NVDA

Unpacking the Latest Options Trading Trends in NVIDIA

Whales with a lot of money to spend have taken a noticeably bullish stance on IonQ.
Looking at options history for IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) we detected 32 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 43% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $432,040 and 27, calls, for a total amount of $1,857,778.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $60.0 for IonQ over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for IonQ's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of IonQ's whale activity within a strike price range from $20.0 to $60.0 in the last 30 days. 
<h3>IonQ Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734713243_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.7</td>
<td>$16.45</td>
<td>$16.7</td>
<td>$60.00</td>
<td>$212.1K</td>
<td>677</td>
<td align="right">150</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$17.45</td>
<td>$16.0</td>
<td>$16.05</td>
<td>$30.00</td>
<td>$160.5K</td>
<td>30</td>
<td align="right">103</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$14.45</td>
<td>$14.3</td>
<td>$14.45</td>
<td>$40.00</td>
<td>$144.5K</td>
<td>4.0K</td>
<td align="right">660</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.8</td>
<td>$16.8</td>
<td>$16.8</td>
<td>$60.00</td>
<td>$134.4K</td>
<td>677</td>
<td align="right">282</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$14.35</td>
<td>$12.8</td>
<td>$12.8</td>
<td>$37.00</td>
<td>$128.0K</td>
<td>18</td>
<td align="right">105</td>
</tr>
</tbody>
</table>

<h3>About IonQ</h3>
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems, and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
In light of the recent options history for IonQ, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is IonQ Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 21,933,609, with IONQ's price up by 21.61%, positioned at $45.92.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About IonQ</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $47.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Craig-Hallum continues to hold a Buy rating for IonQ, targeting a price of $45. 
&#x2A; In a cautious move, an analyst from DA Davidson downgraded its rating to Buy, setting a price target of $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for IonQ with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

IONQ

IonQ Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bullish stance on Freeport-McMoRan.
Looking at options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 31% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $801,900 and 8, calls, for a total amount of $1,305,500.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $35.0 and $50.0 for Freeport-McMoRan, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Freeport-McMoRan's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freeport-McMoRan's whale activity within a strike price range from $35.0 to $50.0 in the last 30 days. 
<h3>Freeport-McMoRan Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734713237_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.86</td>
<td>$1.76</td>
<td>$1.85</td>
<td>$45.00</td>
<td>$925.0K</td>
<td>6.6K</td>
<td>5.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.2</td>
<td>$6.05</td>
<td>$6.05</td>
<td>$40.00</td>
<td>$256.5K</td>
<td>6.5K</td>
<td>424</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.2</td>
<td>$6.0</td>
<td>$6.05</td>
<td>$40.00</td>
<td>$198.4K</td>
<td>6.5K</td>
<td>752</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$12.25</td>
<td>$12.15</td>
<td>$12.25</td>
<td>$50.00</td>
<td>$112.7K</td>
<td>4.6K</td>
<td>92</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.13</td>
<td>$1.09</td>
<td>$1.11</td>
<td>$40.00</td>
<td>$103.1K</td>
<td>8.0K</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2023, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. About 75% of 2023 revenue was from copper, with a further 15% from gold and about 10% from molybdenum. It had about 25 years of copper reserves at end December 2023. we expect it to sell similar amounts of copper midcycle in 2028, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Freeport-McMoRan</h3>
<ul>
<li>Trading volume stands at 6,932,354, with FCX's price up by 2.25%, positioned at $39.1.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Freeport-McMoRan with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Freeport-McMoRan

Stephens &amp; Co. analyst Jeff Garro initiates coverage on OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight rating and announces Price Target of $5.5.

OPRX

Stephens & Co. Initiates Coverage On OptimizeRx with Equal-Weight Rating, Announces Price Target of $5.5

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) stock is trading slightly higher on Friday after the company reported second-quarter earnings on Thursday after the bell and announced plans to separate FedEx Freight. Here&#8217;s what you <a href="https://www.benzinga.com//node/42605034">need to know</a>.
FedEx reported adjusted earnings per share of $4.05, beating analyst estimates of $3.91. In addition, the company reported sales of $22 billion, missing analyst estimates of $22.11 billion.
The company also announced plans to separate FedEx Freight and create a second publicly traded company. FedEx plans to execute this separation within the next 18 months. 
The company believes the separation will enable more customized operational execution and allow for more focused investment and capital strategies to better meet the specific needs of both global parcel delivery and Less Than Truckload freight markets. It will also maintain the strategic benefits of working together on key commercial, operational and technology initiatives.
Analyst Changes: Following the earnings report, several analysts issued <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">price target adjustments</a>.
<ul>
<li>Loop Capital analyst Rick Paterson upgraded FedEx from a Hold rating to a Buy rating and raised the price target from&nbsp;$288&nbsp;to&nbsp;$365.</li>
<li>Wells Fargo analyst Christian Wetherbee maintained an Equal-Weight rating on FedEx and raised the price target from&nbsp;$305&nbsp;to&nbsp;$320.</li>
<li>UBS analyst Thomas Wadewitz maintained a Buy rating on FedEx and raised the price target from&nbsp;$311&nbsp;to&nbsp;$350.</li>
<li>Stifel analyst J. Bruce Chan maintained a Buy rating on FedEx and raised the price target from&nbsp;$321&nbsp;to&nbsp;$368.</li>
</ul>
The company revised its outlook for the 2025 fiscal-year, now expecting nearly flat revenue year over year, compared to its previous expectation of a low single-digit percentage increase. FedEx forecasts adjusted earnings per share of $16.45 to $17.45, compared to its prior guidance of $17.90 to $18.90.
See Also: <a href="https://www.benzinga.com/24/12/42619842/quantum-computing-to-raise-gross-proceeds-worth-29-million-after-registering-shares-for-resale-whats-going-on">What&#8217;s Going On With Quantum Computing Stock Today?</a>
FDX Price Action: At the time of writing, FedEx stock is trading 1.1% higher at $278.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Flickr

What's Going On With FedEx Stock Friday?

Stephens &amp; Co. analyst Jeff Garro initiates coverage on IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Overweight rating and announces Price Target of $250.

Stephens & Co. Initiates Coverage On IQVIA Hldgs with Overweight Rating, Announces Price Target of $250

Whales with a lot of money to spend have taken a noticeably bullish stance on Adobe.
Looking at options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 31% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $1,495,126 and 8, calls, for a total amount of $393,043.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $580.0 for Adobe during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Adobe options trades today is 822.94 with a total volume of 2,453.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Adobe's big money trades within a strike price range of $300.0 to $580.0 over the last 30 days.
<h3>Adobe Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734712935_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$437.50</td>
<td>$135.0K</td>
<td>1.5K</td>
<td align="right">354</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$22.9</td>
<td>$20.95</td>
<td>$22.9</td>
<td>$470.00</td>
<td>$109.9K</td>
<td>96</td>
<td align="right">50</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$39.0</td>
<td>$35.7</td>
<td>$39.0</td>
<td>$400.00</td>
<td>$89.7K</td>
<td>309</td>
<td align="right">23</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$81.6</td>
<td>$75.6</td>
<td>$77.7</td>
<td>$500.00</td>
<td>$85.4K</td>
<td>1.2K</td>
<td align="right">11</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$7.55</td>
<td>$8.3</td>
<td>$300.00</td>
<td>$83.0K</td>
<td>592</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
In light of the recent options history for Adobe, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Adobe</h3>
<ul>
<li>With a volume of 1,992,587, the price of ADBE is up 1.97% at $446.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Adobe</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $599.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Adobe, maintaining a target price of $605. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Adobe with a target price of $600. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Adobe with a target price of $600. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Adobe, which currently sits at a price target of $600. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Adobe with a target price of $590. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Adobe with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ADBE

Market Whales and Their Recent Bets on ADBE Options

Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) price slump has raised concerns, but its growing user base and positive long-term outlook suggest potential <a href="https://www.benzinga.com/money/pepe-price-prediction">for future gains</a>.
What Happened: Lookonchain <a href="https://x.com/lookonchain/status/1869580682101764212">data</a> reveals that a whale deposited 150 billion PEPE (worth $2.72 million) into Binance to cut losses amid the price drop. 
Earlier, on Nov. 28, the whale had withdrawn 150 billion PEPE (valued at $2.94 million) and 60 billion SHIB (worth $1.52 million) from Binance. 
At current prices, the whale is facing a $219,000 loss on PEPE and $136,000 loss on SHIB.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001643</td>
<td>$6.9 billion</td>
<td>-12.5%&nbsp;</td>
<td>-31.6%&nbsp;</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3094</td>
<td>$45.7 billion</td>
<td>-11.2%&nbsp;</td>
<td>-23.3%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002124</td>
<td>$12.5 billion</td>
<td>-9.7%&nbsp;</td>
<td>-24%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Davie Satoshi, a crypto trader, believes that Pepe's drop from its all-time high indicates the end of the first uptrend. 
He sees the second wave as a potential precursor to a new all-time high, maintaining a positive outlook and views the current correction as a healthy reset and an opportunity for accumulation.
Satoshi also <a href="https://x.com/NFTdavie/status/1869912964364443888">notes</a> that the momentum built from these resets positions Pepe for potential growth toward a $100 billion market cap.
Seth, another crypto trader, <a href="https://x.com/seth_fin/status/1870046113111163276">pointed</a> out that Pepe has been trading within a channel since March. 
The price recently retested the top of this channel and was rejected, now testing the mid-channel again. 
The 1-day RSI is at a level similar to past bounces, suggesting a potential recovery. However, the outlook remains dependent on broader market trends like Ethereum, Bitcoin and the S&amp;P500.
Statistics: Plazma <a href="https://x.com/Plazma0x/status/1869869830687371618">reported</a> that 1,059 new Pepe holders joined the community, bringing the total to over 1,100 new holders as of Dec.19. 
Robinhood now holds 3.1% of the PEPE supply, indicating strong retail interest.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42411112/shiba-inu-pepe-or-bonk-ranking-reddits-most-popular-meme-coins">Shiba Inu, Pepe Or Bonk? Ranking Reddit&#8217;s Most Popular Meme Coins</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Pepe Crypto Down 12%: Healthy Correction Or Price Crash?

BMO Capital analyst Keith Bachman maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Market Perform and raises the price target from $390 to $425.

BMO Capital Maintains Market Perform on Accenture, Raises Price Target to $425

BMO Capital analyst Andrew Strelzik maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Market Perform and raises the price target from $165 to $175.

BMO Capital Maintains Market Perform on Darden Restaurants, Raises Price Target to $175

Stephens &amp; Co. analyst Daniel Imbro maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and lowers the price target from $350 to $345.

Stephens & Co. Maintains Overweight on FedEx, Lowers Price Target to $345

BMO Capital analyst Fadi Chamoun maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Market Perform and raises the price target from $300 to $330.

BMO Capital Maintains Market Perform on FedEx, Raises Price Target to $330

Citigroup analyst Ronald Josey maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $120 to $200.

RDDT

Citigroup Maintains Buy on Reddit, Raises Price Target to $200

BMO Capital analyst Evan Seigerman maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Outperform and lowers the price target from $566 to $520.

VRTX

BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520

Citigroup analyst Scott Gruber maintains Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) with a Buy and lowers the price target from $110 to $95.

WFRD

Citigroup Maintains Buy on Weatherford International, Lowers Price Target to $95

Kairos Pharma sets terms for $6M proposed IPO

IPO roundup: NVL, TEM, and more

Wall Street Breakfast: The Week Ahead

IPO Roundup: Bicara Therapeutics, Kairos Pharma and more

Kairos Pharma prices $6.2M IPO

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Kairos Pharma (KAPA) announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading ...

Kairos Pharma approved to dual list on Upstream

Kairos Pharma (KAPA) has selected IBN to spearhead its corporate communications efforts. Kairos Pharma's development pipeline targets drug resistan...

Kairos Pharma selects IBN for corporate communications efforts

AAPL

ADMA

ALMS

BCAX

BIOA

BRTH

CBUS

CGON

CIIT

CJOY

CRMT

CUPR

CUTR

DLTR

DRDBU

EBAY

EHGO

ELOG

EMPG

EQVU

FBGL

FLAI

GLXG

GRDN

GTHX

INHD

IREN

KAPA

KROS

KYTX

LBRJ

LGCY

MANU

MAXN

MIMI

MOOV

NVRI

ORCL

PATH

PLAY

PSTG

PTLE

QGEN

RBRK

RDACU

SVCO

TELO

TRUP

TSX:MKR

UEOP

WKME

YMAT

ZBIO

ZSPC

IPOs

Press Releases

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges

Comments

Kairos Pharma

Kairos Pharma (KAPA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL